Cargando…

Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review

Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available. A new drug class of neprilysin inhibitors as...

Descripción completa

Detalles Bibliográficos
Autores principales: Gangnus, Tanja, Burckhardt, Bjoern B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361796/
https://www.ncbi.nlm.nih.gov/pubmed/30761275
http://dx.doi.org/10.3389/fped.2018.00420
_version_ 1783392741649022976
author Gangnus, Tanja
Burckhardt, Bjoern B.
author_facet Gangnus, Tanja
Burckhardt, Bjoern B.
author_sort Gangnus, Tanja
collection PubMed
description Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available. A new drug class of neprilysin inhibitors as fixed-dose combination (Sacubitril/valsartan) has been introduced and is currently being investigated in children suffering from heart failure. Atrial Natriuretic Peptide (ANP) is discussed as a more useful alternative to BNP because it may grants better insights into the effects of this treatment. Thus, this review aimed to provide an overview of the current knowledge concerning ANP in pediatric heart failure and compares its suitability regarding diagnosis and prognosis of heart failure. A literature search using PubMed resulted in 147 publications of which 22 studies were classified as relevant. The review presents available ANP, NT-proANP, and MR-proANP level data in children (0–18 years). Summarizing, ANP shows only minor differences as marker for diagnosing and monitoring pediatric heart failure if compared to BNP. Due to its fast release, ANP offers the advantage of displaying rapid changes during therapy or operation. ANP is -like the other natriuretic peptides- influenced by age, presenting with the highest levels in very young infants. ANP also correlates with atrial pressure and volume overload in children. In addition, ANP determination in saliva appears to be a promising alternative to blood sampling. Similarly to NT-proBNP, NT-proANP, and MR-proANP offer better stability but only few data has been published in children and thus their potential is only presumable so far.
format Online
Article
Text
id pubmed-6361796
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63617962019-02-13 Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review Gangnus, Tanja Burckhardt, Bjoern B. Front Pediatr Pediatrics Although B-type Natriuretic Peptide (BNP), N-terminal-proBNP (NT-proBNP), and mid-regional-proANP (MR-proANP) are included in current guidelines on heart failure in adults, no guideline considering these biomarkers in pediatric heart failure is available. A new drug class of neprilysin inhibitors as fixed-dose combination (Sacubitril/valsartan) has been introduced and is currently being investigated in children suffering from heart failure. Atrial Natriuretic Peptide (ANP) is discussed as a more useful alternative to BNP because it may grants better insights into the effects of this treatment. Thus, this review aimed to provide an overview of the current knowledge concerning ANP in pediatric heart failure and compares its suitability regarding diagnosis and prognosis of heart failure. A literature search using PubMed resulted in 147 publications of which 22 studies were classified as relevant. The review presents available ANP, NT-proANP, and MR-proANP level data in children (0–18 years). Summarizing, ANP shows only minor differences as marker for diagnosing and monitoring pediatric heart failure if compared to BNP. Due to its fast release, ANP offers the advantage of displaying rapid changes during therapy or operation. ANP is -like the other natriuretic peptides- influenced by age, presenting with the highest levels in very young infants. ANP also correlates with atrial pressure and volume overload in children. In addition, ANP determination in saliva appears to be a promising alternative to blood sampling. Similarly to NT-proBNP, NT-proANP, and MR-proANP offer better stability but only few data has been published in children and thus their potential is only presumable so far. Frontiers Media S.A. 2019-01-29 /pmc/articles/PMC6361796/ /pubmed/30761275 http://dx.doi.org/10.3389/fped.2018.00420 Text en Copyright © 2019 Gangnus and Burckhardt. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Gangnus, Tanja
Burckhardt, Bjoern B.
Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
title Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
title_full Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
title_fullStr Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
title_full_unstemmed Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
title_short Potential and Limitations of Atrial Natriuretic Peptide as Biomarker in Pediatric Heart Failure—A Comparative Review
title_sort potential and limitations of atrial natriuretic peptide as biomarker in pediatric heart failure—a comparative review
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361796/
https://www.ncbi.nlm.nih.gov/pubmed/30761275
http://dx.doi.org/10.3389/fped.2018.00420
work_keys_str_mv AT gangnustanja potentialandlimitationsofatrialnatriureticpeptideasbiomarkerinpediatricheartfailureacomparativereview
AT burckhardtbjoernb potentialandlimitationsofatrialnatriureticpeptideasbiomarkerinpediatricheartfailureacomparativereview